Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MME | P08473 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13679360 | 0.85 | KMT2A (0.45) | MEN1KMT2AESR1ESR2ALDH1A1 | |
| SCHEMBL10544102 | 0.84 | CYP1A2 (0.50) | POLBMEN1KMT2AALDH1A1MAPT | |
| SCHEMBL399975 | 0.83 | FOLH1 (0.48) | POLBMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL1887761 | 0.83 | HDAC1 (0.50) | HDAC1HDAC6POLBMMEESR1 | |
| SCHEMBL6168226 | 0.83 | MME (0.56) | MME | |
| SCHEMBL6174032 | 0.79 | HDAC1 (0.47) | HDAC1HDAC6POLBTDP1MME | |
| Iodide SCHEMBL401190 | 0.78 | HDAC1 (0.46) | HDAC1HDAC6POLBTDP1MME | |
| SCHEMBL8214773 | 0.77 | LTA4H (0.61) | — | |
| SCHEMBL6946548 | 0.77 | PTPRB (0.58) | HDAC1HDAC6POLBTDP1MEN1 | |
| SCHEMBL1749708 | 0.76 | HDAC1 (0.52) | HDAC1HDAC6POLBTDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101665-B2 | Process for synthesis of tritiated and deuterated thiorphan and acetorphan | ROCHE PALO ALTO LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | ROCHE PALO ALTO LLC | 2011-12-29 | — | — | US | disclosed |
| WO-2009077386-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319656-A1 | PROCESS FOR SYNTHESIS OF TRITIATED AND DEUTERATED THIORPHAN AND ACETORPHAN | NAT1, ZRANB2, TXN | HDAC1 343/4885HDAC6 806/4885POLB 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.